AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Study acronym: AMBITION 7
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Novo Nordisk
269 trials monitored
See 14 trials at risk
Diabetes
5,133 trials monitored
See 238 trials at risk
Type 2 Diabetes
2,254 trials monitored
See 117 trials at risk
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.
Trial Details
NCT Number NCT07797335
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Type 2 Diabetes, Cardiovascular Risk
Related terms Diabetes Mellitus, Type 2
Enrollment 1,778 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov